Labcorp Alzheimer’s Blood Test And Neurology Hire Spark Valuation Debate

Simply Wall St

Thu, February 19, 2026 at 2:12 PM GMT+9 2 min read

In this article:

LH

+0.76%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Labcorp Holdings (NYSE:LH) launched the first FDA cleared blood test to aid in the initial assessment of Alzheimer’s disease, the Elecsys pTau-181 test, with nationwide availability.

The company also appointed Dr. John H. Sampson, a leading neurologist and researcher, to its Board of Directors.

Labcorp, a large player in diagnostics and central laboratory services, is moving deeper into neurology focused testing with this Alzheimer’s blood test. The test offers a less invasive option compared with traditional imaging and procedures, which could make early assessment more accessible in primary care settings.

For investors watching NYSE:LH, the combination of a new Alzheimer’s assessment tool and the addition of Dr. Sampson reflects continued attention to complex disease areas. As adoption patterns, reimbursement decisions, and physician uptake develop, this may become an important reference point when considering Labcorp’s role in advanced diagnostics.

Stay updated on the most important news stories for Labcorp Holdings by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Labcorp Holdings.

NYSE:LH 1-Year Stock Price Chart

Does the team leading Labcorp Holdings have what it takes? See our full breakdown of the management team’s track record and compensation.

Quick Assessment

**⚖️ Price vs Analyst Target**: Labcorp trades at US$278.76 versus a consensus target of US$304.59, around 9% below where analysts see it.

**✅ Simply Wall St Valuation**: Shares are flagged as undervalued, trading about 28.8% below the platform's estimated fair value.

**✅ Recent Momentum**: The stock has returned about 2.9% over the last 30 days.

To explore whether it may be the right time to buy, sell or hold Labcorp Holdings, you can review Simply Wall St’s company report for the latest analysis of Labcorp Holdings’s fair value.

Key Considerations

📊 The FDA-cleared Alzheimer’s blood test and Dr. Sampson’s appointment both reinforce Labcorp’s focus on complex diagnostic areas such as neurology.

📊 It may be useful to monitor test adoption, reimbursement coverage, and how this offering influences revenue mix versus the current US$13.95b in sales.

⚠️ The company carries a high level of debt, so investors may want to see how any new growth initiatives balance against leverage.

Dig Deeper

For the full picture including more risks and potential rewards, check out the complete Labcorp Holdings analysis. You can also visit the community page for Labcorp Holdings to see how other investors believe this latest news will impact the company’s narrative.

Story Continues  

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include LH.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info